MAP kinase-activated protein kinase 5 · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14MAP kinase-activated protein kinase 5 shows clinical signal disease relevance led by rheumatoid arthritis. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q8IW41. Start with rheumatoid arthritis, then reuse UniProt Q8IW41 as the stable protein anchor across project notes and exports.
Start with rheumatoid arthritis, then reuse UniProt Q8IW41 as the stable protein anchor across project notes and exports.
MAP kinase-activated protein kinase 5 shows clinical signal disease relevance led by rheumatoid arthritis. 1 linked drug remains visible in the same block.
Start review with rheumatoid arthritis because it currently carries clinical signal support. Linked drugs include GLPG-0259. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyMAP kinase-activated protein kinase 5
Review this target as MAP kinase-activated protein kinase 5, mapped to UniProt Q8IW41. Sequence length is 473 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats MAP kinase-activated protein kinase 5 as ChEMBL target CHEMBL3094, mapped to UniProt Q8IW41. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether MAP kinase-activated protein kinase 5 is the right protein anchor across sources, using UniProt Q8IW41 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why rheumatoid arthritis is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | MAP kinase-activated protein kinase 5 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | Q8IW41 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | MAP kinase-activated protein kinase 5 |
| UniProt Accession | Q8IW41 |
| Component Type | Protein |
| Sequence Length | 473 aa |
MAP kinase-activated protein kinase 5
Review this target as MAP kinase-activated protein kinase 5, mapped to UniProt Q8IW41. Sequence length is 473 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
MAP kinase-activated protein kinase 5 shows clinical signal disease relevance led by rheumatoid arthritis.
Start review with rheumatoid arthritis because it currently carries clinical signal support. Linked drugs include GLPG-0259. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL1231206 | 8.3 | IC50 | 5.0 | Preclinical |
| CHEMBL259084 | 8.1 | Kd | 8.0 | Preclinical |
| CHEMBL1978448 | 8.0 | Ki | 10.0 | Preclinical |
| CHEMBL461139 | 7.62 | IC50 | 24.0 | Preclinical |
| CHEMBL461140 | 7.55 | IC50 | 28.0 | Preclinical |
| CHEMBL5653589 | 7.36 | Kd | 43.66 | Preclinical |
| CHEMBL1997129 | 7.2 | Ki | 63.1 | Preclinical |
| CHEMBL226403 | 7.2 | Ki | 63.1 | Preclinical |
| CHEMBL514499 | 7.2 | Ki | 63.1 | Preclinical |
| CHEMBL1975138 | 7.1 | Ki | 79.43 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 344 | 51 | 6.1 |
| assay format | 43 | 16 | 6.0 |
| cell-based format | 25 | 2 | 5.0 |
| subcellular format | 1 | 4 | 6.1 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 6 | 1 | 6.3 |
| assay format | 1 | 41 | 6.3 |